Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NEKTAR THERAPEUTICS (NKTR)

Nektar wins $90 million jury verdict against Eli Lilly over rezpegaldesleukin license

Positive Impact 4 of 5 legal/regulatory Written later

Nektar Therapeutics disclosed that a federal jury found Eli Lilly breached the implied covenant of good faith and fair dealing in their license agreement for rezpegaldesleukin. The jury awarded Nektar $90 million in damages plus interest, to be determined by the court. The verdict remains subject to post-trial proceedings and possible appeal, so the amount Nektar ultimately receives is not yet certain.

Key points

  • Jury verdict returned September 24, 2026 in Nektar Therapeutics v. Eli Lilly & Co., Case No. 3:23-cv-03943-JD
  • Jury awarded Nektar $90 million in damages plus interest, with interest to be set by the District Court
  • Verdict is subject to post-trial proceedings and any resulting judgment may be appealed

The filing

CompanyNEKTAR THERAPEUTICS (NKTR)
Form8-K, current report
Filed with the SECSep 25, 2026, 7:00 AM ET
Accession number0001213900-26-103215

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.